BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Position in Humana Inc. (NYSE:HUM)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its position in Humana Inc. (NYSE:HUM) by 83.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,678 shares of the insurance provider’s stock after selling 73,261 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Humana were worth $5,484,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of HUM. Kestra Private Wealth Services LLC boosted its holdings in Humana by 9.3% in the 4th quarter. Kestra Private Wealth Services LLC now owns 1,883 shares of the insurance provider’s stock valued at $862,000 after purchasing an additional 160 shares during the period. Brighton Jones LLC raised its position in shares of Humana by 6.8% in the fourth quarter. Brighton Jones LLC now owns 470 shares of the insurance provider’s stock worth $215,000 after buying an additional 30 shares in the last quarter. Essex Financial Services Inc. boosted its stake in Humana by 20.0% during the fourth quarter. Essex Financial Services Inc. now owns 618 shares of the insurance provider’s stock valued at $283,000 after buying an additional 103 shares during the period. Benjamin F. Edwards & Company Inc. grew its position in Humana by 14.8% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 490 shares of the insurance provider’s stock worth $225,000 after buying an additional 63 shares in the last quarter. Finally, Merit Financial Group LLC increased its stake in Humana by 2.1% in the 4th quarter. Merit Financial Group LLC now owns 1,770 shares of the insurance provider’s stock worth $810,000 after acquiring an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $354.47 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.67. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The firm has a 50-day moving average of $367.67 and a 200 day moving average of $346.81. The company has a market cap of $42.71 billion, a P/E ratio of 22.07, a PEG ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $8.94 EPS. On average, sell-side analysts forecast that Humana Inc. will post 16.14 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.00%. Humana’s payout ratio is 22.04%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HUM. Piper Sandler started coverage on Humana in a report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective for the company. Deutsche Bank Aktiengesellschaft lifted their price target on Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. TD Cowen raised their price objective on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Truist Financial upped their target price on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research note on Monday, July 15th. Finally, Baird R W raised shares of Humana to a “hold” rating in a research note on Thursday, May 30th. Thirteen research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $396.35.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.